Category: Laser/Light-based Devices
Wall Street rallies as dental laser maker Biolase raises $12 million through a private placement round, even as the company deals with an ongoing civil war involving ousted CEO Federico Pignatelli.
California-based Biolase (NSDQ:BIOL) announced today that it secured $12 million in a private placement funding round, even as the company weathers the internal tumult following the ouster of former CEO Federico Pignatelli.
Ousted Biolase CEO Federico Pignatelli launches an investigation into the device maker, saying he suspects "wrongdoing, mismanagement and corporate governance failures."
Shares of Biolase (NSDQ:BIOL) got a modest boost today, even as a company insider announced a far-reaching investigation into the company's management under the suspicion of wrongdoing.
Biolase CEO Federico Pignatelli is out after a court-ordered shake-up at Biolase.
The boardroom and C-suite at Biolase (NSDQ:BIOL) got a shake-up this week following a Delaware Supreme Court decision in a lawsuit filed by Oracle Partners earlier this year.
Biolase vows to amend its complaint after a federal judge shoots down its false advertising and defamation claims against rival dental laser maker Fotona.
A federal judge this month dismissed a Biolase (NSDQ:BIOL) lawsuit alleging false advertising and defamation by dental laser rival Fotona, but left the door open for an amended complaint.
Biolase steadies itself against a proxy war filed by activist majority shareholder Oracle Partners over alleged manipulation of the board of directors.
Medical lasers maker Biolase is still examining "strategic alternatives" for the company as its slashes about $1.3 million from its payroll and posts continued quarterly losses.
California medtech company Biolase (NSDQ:BIOL) is looking to slim down ahead of a potential acquisition as the company examines its "strategic alternatives."
Lumenis prices its initial public offering at $12 per share, meaning it will raise about 20% less from the IPO; shares gain nearly 9% in 1st trading.
Lumenis Ltd. today priced its initial public offering at $12 per share, 20% under the low end of the prior $15-$17 range set by the Israeli maker of medical lasers.
Lumenis shares, trading under the "LMNS" symbol on the NASDAQ exchange, opened up 4.2% at $12.50 today and were fetching $13.05 apiece as of about 11:20 a.m., up 8.8%.